Tirzepatide
Dual GLP-1/GIP agonist reference standard for receptor research.
Tirzepatide is a synthetic dual GLP-1 and GIP receptor agonist. Supplied as a reference standard for in vitro receptor binding, metabolic signaling, and comparative agonist studies. ≥99% purity by HPLC, LC-MS confirmed.
Tirzepatide: Dual-Action Research Peptide
Tirzepatide is a complex synthetic peptide that functions as a dual agonist at the GLP-1 receptor and GIP receptor, originally developed by Eli Lilly (marketed as Mounjaro). With a molecular weight of approximately 4,813 Da, tirzepatide represents significantly more structural complexity than single-target peptide therapeutics. Its dual mechanism of action across two distinct metabolic pathways has made it a major subject of research in models examining glucose homeostasis, weight regulation, and metabolic disease phenotypes in rodents and non-human primates.
Published research on tirzepatide has expanded rapidly since development, with studies examining its effects on insulin secretion, beta-cell function, and weight-related metabolic parameters in preclinical models. The compound has been evaluated in diet-induced obesity models, high-fat feeding protocols, and genetic models of metabolic dysfunction. Research has also explored the relative contribution of GLP-1 versus GIP signaling to its observed effects. As a complex synthetic peptide, tirzepatide presents unique chemistry that makes it distinct from naturally-derived peptides—this complexity underscores the importance of rigorous purity analysis. For detailed research context, please see our tirzepatide research article.
Sourcing tirzepatide requires particular attention to analytical verification, given the molecule's synthetic complexity. Researchers should insist on HPLC assay data confirming purity, and—given the multi-step synthesis pathway—verification of identity by mass spectrometry is strongly recommended. Certificate of Analysis (CoA) documentation should clearly specify molecular weight confirmation, amino acid analysis if applicable, and sterility/endotoxin testing results. Many suppliers lack rigorous third-party verification; we maintain full analytical transparency with publicly accessible COA data for every batch.
Storage conditions for tirzepatide mirror those of other peptides: -20°C or below prior to reconstitution, and 2-8°C for reconstituted solutions with a 2-4 week usable window. Tirzepatide is more sensitive to pH fluctuations than some peptides, so reconstitution vehicle selection matters—bacteriostatic water at physiologic pH is standard. Given the compound's cost and complexity, minimize handling and avoid unnecessary freeze-thaw cycles. For comparative research and alternative dual-agonist compounds, explore semaglutide and retatrutide.
Lone Star Peptide ships same-day to research institutions across all of Texas. Same-state logistics mean shorter cold-chain transit and faster delivery than any out-of-state supplier — with COA documentation that meets institutional procurement standards statewide.
Tested
Included
Houston
Tirzepatide: Dual-Action Research Peptide
Tirzepatide is a complex synthetic peptide that functions as a dual agonist at the GLP-1 receptor and GIP receptor, originally developed by Eli Lilly (marketed as Mounjaro). With a molecular weight of approximately 4,813 Da, tirzepatide represents significantly more structural complexity than single-target peptide therapeutics. Its dual mechanism of action across two distinct metabolic pathways has made it a major subject of research in models examining glucose homeostasis, weight regulation, and metabolic disease phenotypes in rodents and non-human primates.
Published research on tirzepatide has expanded rapidly since development, with studies examining its effects on insulin secretion, beta-cell function, and weight-related metabolic parameters in preclinical models. The compound has been evaluated in diet-induced obesity models, high-fat feeding protocols, and genetic models of metabolic dysfunction. Research has also explored the relative contribution of GLP-1 versus GIP signaling to its observed effects. As a complex synthetic peptide, tirzepatide presents unique chemistry that makes it distinct from naturally-derived peptides—this complexity underscores the importance of rigorous purity analysis. For detailed research context, please see our tirzepatide research article.
Sourcing tirzepatide requires particular attention to analytical verification, given the molecule's synthetic complexity. Researchers should insist on HPLC assay data confirming purity, and—given the multi-step synthesis pathway—verification of identity by mass spectrometry is strongly recommended. Certificate of Analysis (CoA) documentation should clearly specify molecular weight confirmation, amino acid analysis if applicable, and sterility/endotoxin testing results. Many suppliers lack rigorous third-party verification; we maintain full analytical transparency with publicly accessible COA data for every batch.
Storage conditions for tirzepatide mirror those of other peptides: -20°C or below prior to reconstitution, and 2-8°C for reconstituted solutions with a 2-4 week usable window. Tirzepatide is more sensitive to pH fluctuations than some peptides, so reconstitution vehicle selection matters—bacteriostatic water at physiologic pH is standard. Given the compound's cost and complexity, minimize handling and avoid unnecessary freeze-thaw cycles. For comparative research and alternative dual-agonist compounds, explore semaglutide and retatrutide.
FOR RESEARCH USE ONLY, Tirzepatide is supplied exclusively for in vitro and laboratory research applications. Not approved by the FDA for human consumption or therapeutic use. Not a drug, supplement, or medical treatment. Purchasers are responsible for compliance with all applicable regulations.